09.06.2026
The excessive Dialysis Product Pricing case targets Adcock Ingram, with a possible 10% turnover penalty and wider renal care cost impacts.
04.11.2025
Adcock Ingram delisting from the JSE is confirmed for November 11. Learn about the impact of the Natco Pharma acquisition.
15.10.2025
Shareholders have approved the Adcock Ingram takeover by Natco Pharma, marking a new chapter for the pharmaceutical company.
24.08.2025
Adcock Ingram reports steady annual profits as winter demand for Panado and Corenza-C drives growth in the second half.
30.07.2025
Learn how Bidvest's partnership with Natco Pharma impacts Adcock Ingram and shareholder rights amid a new takeover bid.
24.07.2025
Adcock Ingram is set to delist from the JSE as Natco Pharma partners with Bidvest in a major take-private deal.